<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00915174</url>
  </required_header>
  <id_info>
    <org_study_id>MRZ 92579/TI/1005</org_study_id>
    <nct_id>NCT00915174</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Effects of Neramexane on the Pharmacokinetics of a Combined Drospirenone/Ethinyl Estradiol Oral Contraceptive in Healthy Female Subjects</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merz Pharmaceuticals GmbH</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merz Pharmaceuticals GmbH</source>
  <brief_summary>
    <textblock>
      Primary:&#xD;
&#xD;
      To assess the effects of repeated dose of Neramexane on the steady-state pharmacokinetics of&#xD;
      Drospirenone [DRSP] and Ethinyl Estradiol [EE]&#xD;
&#xD;
      Secondary:&#xD;
&#xD;
      To assess safety and tolerability of concomitant repeated dose treatments of Neramexane and a&#xD;
      fixed-combinational DRSP- and EE-containing oral contraceptive [OC] (Yasmin®)&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area Under Curve within a dose interval (AUC, 0-tau) and Maximum Plasma Concentration at Steady State (Cmax) of Drospirenone (DRSP) and Ethinyl Estradiol (EE)</measure>
    <time_frame>24 hours</time_frame>
  </primary_outcome>
  <enrollment type="Actual">36</enrollment>
  <condition>Healthy</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neramexane</intervention_name>
    <description>25 mg q.d., 3 days 2 x 25 mg b.i.d., 11 days</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Healthy adult female subject of child bearing potential (including subject with tubal&#xD;
             ligation), white origin, who is able to read, to write and fully understand German&#xD;
             language&#xD;
&#xD;
          -  Aged 18 to 45 years (both inclusive)&#xD;
&#xD;
          -  BMI of 18-28 kg/m2 and a body weight of 50-90 kg (both inclusive)&#xD;
&#xD;
          -  The subject is required&#xD;
&#xD;
          -  To have taken a DRSP/EE- containing OC for at least two dosing cycles&#xD;
&#xD;
          -  To agree using reliable non hormonal birth control methods from Day -1 of study Period&#xD;
             1 until the Final Examination (e.g. non-hormonal IUD, double barrier method [e.g.&#xD;
             condom with spermicide or diaphragm with spermicide], sexual abstinence). Women with&#xD;
             tubal ligation or sterilized partner do not need an additional birth control method&#xD;
&#xD;
          -  Willing and able to provide written informed consent after having been informed of the&#xD;
             requirements and the restrictions of the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of clinically relevant allergy or known hypersensitivity to&#xD;
             Neramexane/Memantine/ Amantadine and their derivatives&#xD;
&#xD;
          -  Hypersensitivity to Quinine&#xD;
&#xD;
          -  History of clinically relevant allergy or known hypersensitivity to any inactive&#xD;
             ingredient in any of the used study medications (Neramexane, Yasmin®, Placebo) or tool&#xD;
             substance&#xD;
&#xD;
          -  History of clinically relevant allergy or known hypersensitivity to DRSP/EE&#xD;
&#xD;
          -  Clinically relevant findings on the mammae or genital examination, PAP smear ≥ III&#xD;
&#xD;
          -  Any contraindications against the oral contraceptive:&#xD;
&#xD;
          -  present or past venous thromboses (deep vein thrombosis, pulmonary embolism);&#xD;
&#xD;
          -  present or past arterial thromboses (e.g. myocardial infarction) or their prodromal&#xD;
             stages (e.g. angina pectoris and transitory ischaemic attack);&#xD;
&#xD;
          -  present or past cerebrovascular insult;&#xD;
&#xD;
          -  presence of a serious risk factor or several risk factors for an arterial thrombosis:&#xD;
             diabetes mellitus with vascular changes, severe hypertension, severe lipid metabolism&#xD;
             disturbance;&#xD;
&#xD;
          -  known or suspected genetic or acquired predisposition for venous or arterial&#xD;
             thromboses like APC resistance,&#xD;
&#xD;
          -  known or suspected genetic lack of antithrombin III, lack of protein C, lack of&#xD;
             protein S, hyperhomocysteinaemia and antiphospholipid antibodies (anticardiolipin&#xD;
             antibodies, lupus anticoagulants);&#xD;
&#xD;
          -  present or past pancreatitis if this is accompanied by severe hypertriglyceridaemia;&#xD;
&#xD;
          -  present or past severe hepatic disease as long as the liver function tests have not&#xD;
             normalized;&#xD;
&#xD;
          -  severe renal insufficiency or acute renal failure;&#xD;
&#xD;
          -  present or past hepatic tumors (benign or malign);&#xD;
&#xD;
          -  known or suspected sexual hormone dependent, malign tumors (e.g. of the genital organs&#xD;
             or the mamma);&#xD;
&#xD;
          -  diagnostic not clarified vaginal bleedings;&#xD;
&#xD;
          -  anamnesis of migraine with focal neurologic symptoms;&#xD;
&#xD;
          -  known hereditary angioedema&#xD;
&#xD;
          -  Exposure to another investigational agent within the last two months before Day 1 of&#xD;
             Period 1&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Expert</last_name>
    <role>Study Director</role>
    <affiliation>Merz Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AAIharma Deutschland GmbH &amp; Co. KG</name>
      <address>
        <city>Neu Ulm</city>
        <state>Bavaria</state>
        <zip>89231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <study_first_submitted>June 4, 2009</study_first_submitted>
  <study_first_submitted_qc>June 4, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2009</study_first_posted>
  <last_update_submitted>May 5, 2011</last_update_submitted>
  <last_update_submitted_qc>May 5, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 6, 2011</last_update_posted>
  <responsible_party>
    <name_title>Manager Public Disclosure</name_title>
    <organization>Merz Pharmaceuticals GmbH</organization>
  </responsible_party>
  <keyword>drug-drug interaction study</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

